Abstract
The COVID-19 pandemic brought to the fore the urgent need for vaccine design and delivery platforms that can be rapidly deployed for manufacture and distribution. Though the mRNA and adenoviral vector platforms have been enormously successful to control SARS-CoV-2 viral infections, it is unclear if this could be replicated against more complex pathogens or the emerging variants. Recently, we described a “universal” platform that can incorporate multiple vaccine targets into the same nanoparticle scaffold by CRISPR engineering of bacteriophage T4. A T4-COVID vaccine designed with this technology elicited broad immunogenicity and complete protection against virus challenge in a mouse model. Here, we describe the detailed methodology to generate recombinant bacteriophage T4 backbones using CRISPR that can also be broadly applicable to other bacteriophages that abundantly pervade the Earth.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Zhu N et al (2020) A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382(8):727–733
Zhou P et al (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579:270–273
Li F (2016) Structure, function, and evolution of coronavirus spike proteins. Annu Rev Virol 3(1):237–261
V’Kovski P, Kratzel A, Steiner S, Stalder H, Thiel V (2020) Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol 19:155–170
Chung YH, Beiss V, Fiering SN, Steinmetz NF (2020) COVID-19 vaccine frontrunners and their nanotechnology design. ACS Nano 14(10):12522–12537
Shin MD et al (2020) COVID-19 vaccine development and a potential nanomaterial path forward. Nat Nanotechnol 15(8):646–655
Dong Y et al (2020) A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduct Target Ther 5(1):237
Su S, Du L, Jiang S (2020) Learning from the past: development of safe and effective COVID-19 vaccines. Nat Rev Microbiol 19:211–219
Corbett KS et al (2020) SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586(7830):567–571
Yang J et al (2020) A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature 586(7830):572–577
Ewer KJ et al (2020) T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med 27:270–278
Krammer F (2020) SARS-CoV-2 vaccines in development. Nature 586(7830):516–527
Park KS, Sun X, Aikins ME, Moon JJ (2020) Non-viral COVID-19 vaccine delivery systems. Adv Drug Deliv Rev 169:137–151
Walls AC et al (2020) Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. Cell 183(5):1367–1382.e1317
Sette A, Crotty S (2021) Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 184(4):861–880
Gaebler C et al (2021) Evolution of antibody immunity to SARS-CoV-2. Nature 591(7851):639–644
Tan TK et al (2021) A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses. Nat Commun 12(1):542
Ma X et al (2020) Nanoparticle vaccines based on the receptor binding domain (RBD) and heptad repeat (HR) of SARS-CoV-2 elicit robust protective immune responses. Immunity 53(6):1315–1330.e1319
Zhu J et al (2021) A universal bacteriophage T4 nanoparticle platform to design multiplex SARS-CoV-2 vaccine candidates by CRISPR engineering. Science Advances 7:eabh1547
Ishii T, Yanagida M (1977) The two dispensable structural proteins (soc and hoc) of the T4 phage capsid; their purification and properties, isolation and characterization of the defective mutants, and their binding with the defective heads in vitro. J Mol Biol 109(4):487–514
Fokine A et al (2004) Molecular architecture of the prolate head of bacteriophage T4. Proc Natl Acad Sci U S A 101(16):6003–6008
Fokine A et al (2011) Structure of the three N-terminal immunoglobulin domains of the highly immunogenic outer capsid protein from a T4-like bacteriophage. J Virol 85(16):8141–8148
Li Q, Shivachandra SB, Zhang Z, Rao VB (2007) Assembly of the small outer capsid protein, Soc, on bacteriophage T4: a novel system for high density display of multiple large anthrax toxins and foreign proteins on phage capsid. J Mol Biol 370(5):1006–1019
Tao P et al (2013) In vitro and in vivo delivery of genes and proteins using the bacteriophage T4 DNA packaging machine. Proc Natl Acad Sci U S A 110(15):5846–5851
Tao P et al (2013) Mutated and bacteriophage T4 nanoparticle arrayed F1-V immunogens from Yersinia pestis as next generation plague vaccines. PLoS Pathog 9(7):e1003495
Shivachandra SB et al (2007) Multicomponent anthrax toxin display and delivery using bacteriophage T4. Vaccines 25(7):1225–1235
Tao P et al (2018) A bacteriophage T4 nanoparticle-based dual vaccine against anthrax and plague. MBio 9(5):e01926
Zhu J et al (2019) A prokaryotic-eukaryotic hybrid viral vector for delivery of large cargos of genes and proteins into human cells. Sci Adv 5(8):eaax0064
Tao P, Zhu J, Mahalingam M, Batra H, Rao VB (2018) Bacteriophage T4 nanoparticles for vaccine delivery against infectious diseases. Adv Drug Deliv Rev 145:57–72
Tao P et al (2017) A bivalent anthrax-plague vaccine that can protect against two tier-1 bioterror pathogens, Bacillus anthracis and Yersinia pestis. Front Immunol 8:687
Plattner M et al (2019) Structure and function of the branched receptor-binding complex of bacteriophage CBA120. J Mol Biol 431(19):3718–3739
Tao P, Wu X, Tang WC, Zhu J, Rao V (2017) Engineering of bacteriophage T4 genome using CRISPR-Cas9. ACS Synth Biol 6(10):1952–1961
Liu Y et al (2020) Covalent modifications of bacteriophage genome confer a degree of resistance to bacterial CRISPR systems. J Virol 94:e01630. https://doi.org/10.1128/JVI.01630-20
Gause KT et al (2017) Immunological principles guiding the rational design of particles for vaccine delivery. ACS Nano 11:54–68
Mandala VS et al (2020) Structure and drug binding of the SARS-CoV-2 envelope protein transmembrane domain in lipid bilayers. Nat Struct Mol Biol 27(12):1202–1208
Esvelt KM et al (2013) Orthogonal Cas9 proteins for RNA-guided gene regulation and editing. Nat Methods 10(11):1116–1121
Zhu J, Tao P, Mahalingam M, Rao VB (2020) Preparation of a bacteriophage T4-based prokaryotic-eukaryotic hybrid viral vector for delivery of large cargos of genes and proteins into human cells. Bio-protocol 10(7):e3573
Acknowledgments
This research was supported by NIAID/NIH supplement grant 3R01AI095366-07S1 (subaward: 1100992-100) and in part by NIAID/NIH grants AI111538 and AI081726 and National Science Foundation grant MCB-0923873 to V.B.R.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Zhu, J., Ananthaswamy, N., Jain, S., Batra, H., Tang, WC., Rao, V.B. (2022). CRISPR Engineering of Bacteriophage T4 to Design Vaccines Against SARS-CoV-2 and Emerging Pathogens. In: Thomas, S. (eds) Vaccine Design. Methods in Molecular Biology, vol 2410. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1884-4_10
Download citation
DOI: https://doi.org/10.1007/978-1-0716-1884-4_10
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-1883-7
Online ISBN: 978-1-0716-1884-4
eBook Packages: Springer Protocols